These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. TATA-box dependent trans-activation of the human HSP70 promoter by Myb proteins. Foos G; Natour S; Klempnauer KH Oncogene; 1993 Jul; 8(7):1775-82. PubMed ID: 8510924 [TBL] [Abstract][Full Text] [Related]
6. Constitutive expression of full-length c-Myb transforms avian cells characteristic of both the monocytic and granulocytic lineages. Fu SL; Lipsick JS Cell Growth Differ; 1997 Jan; 8(1):35-45. PubMed ID: 8993832 [TBL] [Abstract][Full Text] [Related]
7. B-MYB transactivates its own promoter through SP1-binding sites. Sala A; Saitta B; De Luca P; Cervellera MN; Casella I; Lewis RE; Watson R; Peschle C Oncogene; 1999 Feb; 18(6):1333-9. PubMed ID: 10022815 [TBL] [Abstract][Full Text] [Related]
8. Dissociation of transcriptional activation and oncogenic transformation by v-Myb. Chen RH; Fields S; Lipsick JS Oncogene; 1995 Nov; 11(9):1771-9. PubMed ID: 7478605 [TBL] [Abstract][Full Text] [Related]
9. B-Myb repressor function is regulated by cyclin A phosphorylation and sequences within the C-terminal domain. Petrovas C; Jeay S; Lewis RE; Sonenshein GE Oncogene; 2003 Apr; 22(13):2011-20. PubMed ID: 12673206 [TBL] [Abstract][Full Text] [Related]
10. Transforming potential of truncated v-myb and stimulation of replication by gag-myb fusion products. Merzak A; Soret J; Martinerie C; Sureau A; Crochet J; Perbal B Oncogene; 1992 Mar; 7(3):535-42. PubMed ID: 1549366 [TBL] [Abstract][Full Text] [Related]
11. The various domains of v-myb and v-ets oncogenes of E26 retrovirus contribute differently, but cooperatively, in transformation of hematopoietic lineages. Domenget C; Leprince D; Pain B; Peyrol S; Li RP; Stehelin D; Samarut J; Jurdic P Oncogene; 1992 Nov; 7(11):2231-41. PubMed ID: 1331935 [TBL] [Abstract][Full Text] [Related]
12. Transcriptional regulation by the carboxyl terminus of c-Myb depends upon both the Myb DNA-binding domain and the DNA recognition site. Dubendorff JW; Lipsick JS Oncogene; 1999 Jun; 18(23):3452-60. PubMed ID: 10376523 [TBL] [Abstract][Full Text] [Related]
13. The oncogenicity of jun. Vogt PK; Bos TJ; Mitsunobu F; Nishimura T; Monteclaro FS; Su HY Princess Takamatsu Symp; 1989; 20():127-34. PubMed ID: 2562177 [TBL] [Abstract][Full Text] [Related]
14. The Myb leucine zipper is essential for leukemogenicity of the v-Myb protein. Bartůnek P; Karafiát V; Dvoráková M; Záhorová V; Mandíková S; Zenke M; Dvorák M Oncogene; 1997 Dec; 15(24):2939-49. PubMed ID: 9416837 [TBL] [Abstract][Full Text] [Related]
15. Transformation by v-Myb. Lipsick JS; Wang DM Oncogene; 1999 May; 18(19):3047-55. PubMed ID: 10378700 [TBL] [Abstract][Full Text] [Related]
17. trans activation of gene expression by v-myb. Ibanez CE; Lipsick JS Mol Cell Biol; 1990 May; 10(5):2285-93. PubMed ID: 2325652 [TBL] [Abstract][Full Text] [Related]
18. v-Myc, but not Max, possesses domains that function in both transcription activation and cellular transformation. Min S; Taparowsky EJ Oncogene; 1992 Aug; 7(8):1531-40. PubMed ID: 1630816 [TBL] [Abstract][Full Text] [Related]
19. Transformation by v-myb correlates with trans-activation of gene expression. Lane T; Ibanez C; Garcia A; Graf T; Lipsick J Mol Cell Biol; 1990 Jun; 10(6):2591-8. PubMed ID: 2160580 [TBL] [Abstract][Full Text] [Related]
20. The v-rel oncogene encodes a cell-specific transcriptional activator of certain promoters. Gélinas C; Temin HM Oncogene; 1988 Oct; 3(4):349-55. PubMed ID: 2856247 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]